Show simple item record

dc.contributor.authorGonzález Domínguez , Raúl 
dc.contributor.authorGarcía Barrera, Tamara 
dc.contributor.authorVitorica, Javier
dc.contributor.authorGómez Ariza, José Luis 
dc.date.accessioned2018-04-10T11:53:41Z
dc.date.available2018-04-10T11:53:41Z
dc.date.issued2015
dc.identifier.citationGonzález Domínguez, R., García Barrera, T., Vitorica, J., Gómez Ariza, J.L.: "Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry". Journal of Pharmaceutical and Biomedical Analysis. Vol. 102, págs. 425-435, (2015). DOI: 10.1016/j.jpba.2014.10.009es_ES
dc.identifier.issn0731-7085
dc.identifier.issn1873-264X (electrónico)
dc.identifier.urihttp://hdl.handle.net/10272/14594
dc.description.abstractThe identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease.es_ES
dc.description.sponsorshipThis work was supported by the projects CTM2012-38720-C03-01 from the Ministerio de Ciencia e Innovacion and P008-FQM-3554 and P009-FQM-4659 from the Consejeria de Innovacion, Ciencia y Empresa (Junta de Andalucia). Raul Gonzalez Dominguez thanks the Ministerio de Educacion for a predoctoral scholarship.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subject.otherMetabolomicses_ES
dc.subject.otherAPP/PS1 micees_ES
dc.subject.otherBrain regionses_ES
dc.subject.otherDirect infusion mass spectrometryes_ES
dc.subject.otherAlzheimer's diseasees_ES
dc.titleMetabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jpba.2014.10.009es_ES
dc.identifier.doi10.1016/j.jpba.2014.10.009
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Ministerio de Ciencia e Innovacion [CTM2012-38720-C03-01]
dc.relation.projectIDinfo:eu-repo/grantAgreement/Consejeria de Innovacion, Ciencia y Empresa (Junta de Andalucia) [P008-FQM-3554, P009-FQM-4659]


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España

Copyright © 2008-2010. ARIAS MONTANO. Repositorio Institucional de la Universidad de Huelva
Contact Us | Send Feedback |